ClinicalTrials.gg
WithdrawnNCT06692413Updated Feb 19, 2026

Withings Devices Follow-up Study - Hypertension

An observational study in Hypertension, sponsored by Withings. Withdrawn at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Withings · Observational

Why this study was withdrawn
The PI couldn't participate to the study finally
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
0
Ages
21 Years and older
Sex
All
01

Study summary

The primary objective is to evaluate the accuracy to predict uncontrolled hypertension with Withings device data.

02

Conditions studied

  • Hypertension

Browse trials for

03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

Browse Hypertension studies →

Lead sponsor

Withings is the lead sponsor of 23 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The population meeting the inclusion criteria will all live in the US, regular and active users of one or several WITHINGS devices, who agreed to receive notifications from Withings Clinical Operations department, and who have previously acquired a WITHINGS device. They will receive a notification through their WITHINGS application, offering them the opportunity to participate in the study. In case of a positive answer, the user will be redirected to the study information sheet.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female who are 21 years of age or older,
  • Participant living in the United States,
  • Participant with data recorded in WITHINGS database,
  • Active WITHINGS device users having at least 2 years of data,
  • Subject able to read, understand, and provide written ,
  • Subject willing and able to participate in the study procedures as described in the consent form,
  • Subject able to communicate effectively with and willing to follow instructions from the study staff.

Exclusion criteria

Exclusion Criteria:

  • Minors under 21 years old,
  • Subject who refused to participate in the study,
  • Subject who did not reply to the questionnaire,
  • Subject who objected to the processing of his or her data after the start of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Withings device users

    Active Withings device users having at least 2 years of device data

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    Users who consent to the study will receive a questionnaire every 3 months

06

What researchers measure

Primary outcomes

  1. Prediction of uncontrolled hypertension

    Correlation between uncontrolled hypertension, Withings data, and survey answers

    Time frame: 2 years

Secondary outcomes

  1. Correlation between Framingham risk score and EQ-5D-5L answers and Withings data

    Correlation between Framingham risk score and EQ-5D-5L answers and Withings data

    Time frame: 2 years

  2. Number of Questionnaires answers per participant

    Number of Questionnaires answers per participant

    Time frame: 2 years

07

Study locations

1 site
  • Yale University Medical School, Department of Neurology
    New Haven, Connecticut 06150, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06692413
Lead sponsor
Withings
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Nov 1, 2024
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024
Last update
Feb 19, 2026

Study contacts

de Havenon, MD
principal investigator · Yale University School of Medicine, Dept of Neurology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion